Aurion Biotech

Aurion Biotech Completes Phase 1 Clinical Trial for HCEC-1 in Corneal Edema

Aurion Biotech has completed its Phase 1 clinical trial (NCT05309135) for HCEC-1, a novel human corneal endothelial cell therapy combined with Rho kinase inhibitor Y-27632, targeting corneal edema secondary to endothelial dysfunction. This milestone de-risks early-stage development, paving the way for potential advancement into later clinical phases and signaling a significant step in regenerative ophthalmic treatments.